Journal for Research in Applied Sciences and Biotechnology

www.jrasb.com

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

Article Review: Biochemical Aspect of Survivin Hormone

Noori Mohammed Aziz[1] and Wisam Sbhan Khalf Mohamed[2]

[1]Department of Chemistry, College of Education for Pure Science, Kirkuk University, Kirkuk, IRAQ.

[2]General Directorate of Education in Kirkuk Governorate, Kirkuk, IRAQ.

[1]Corresponding Author: nooriaziz@uokirkuk.edu.iq

www.jrasb.com || Vol. 1 No. 5 (2022): December Issue

Received: 15-10-2022	**Revised:** 05-11-2022	**Accepted:** 15-11-2022

ABSTRACT

A cancer gene called survivin is muted in cells which have undergone differentiation, but it is highly qualitative sample in the overwhelming proportion of malignancies. Over subsequent decades, there has been a lot of curiosity in it. Inhibiting apoptotic, encouraging mitotic, and increasing vascular formation while producing cytotoxic drugs are several crucial characteristics that define it is a good target. These processes, that together promote carcinogenic behaviour, cover the whole spectrum of carcinogenesis, encompassing growth, migratory, or infiltration. Survivin identification independently or coupled in blood and/or urine has become a diagnostic tool for prostate cancer. Furthermore, a number of researches showed that abnormal survivin transcription is linked to a poor prognosis or radiation/drug resistance. Early findings from approaches that target survivin in the treatment of breast carcinoma are encouraging. In order to clarify how this intriguing chemical performs such contradictory function, researchers outline its involvement in the detection, prognosis, as well as therapy of melanoma in this review.

The IAP enzyme group, which includes the survival protein (SVN), stimulates cell growth or prevents apoptosis. As a biomarker for autoimmune conditions, hyper plasia, or malignancies, accumulation of Survivin is linked to these conditions. Increasingly acknowledged like a tumor-associated antigen (TAA), SVN has emerged as a crucial focus for the detection or management of malignancy.

Keywords- Apoptosis, Survivin, Immunotherapeutic, Endometrial.

I. INTRODUCTION

Blasting analysis of the unexpected query protein reveals the baculovirus IAP repeat (BIR) motif that is a distinctive feature of the regulator of apoptotic group of peptides. Survivin was first found in Dario Altieri's group in 1997 (IAP). Consequently, this recently found protein, which has been assigned the name "Survivin," works as a role in cell survival. It demonstrates that dual activities in the associated apoptosis or cell cycle processes have been preserved across evolutionary time. The 14,796 nucleotides that make up the survivin gene are situated in the 17q25 TATA-less promoter region. Survivin is produced in various malignancies or in embryogenesis; however it is seldom ever seen in cell populations[1]. It so performs a crucial part in the development of cancer.

Following cardiac illnesses, cancer continues to be the second greatest cause of mortality worldwide. Survivin, a particular representative of the inhibitor of apoptosis (IAP) protein relatives, is now known to perform a role in a variety of biological procedures as well as clinical manifestations like the development of cancer in various human organ systems or cell types. This growing body of substantiation supports this theory. The X-linked inhibitor of apoptosis (XIAP), cIAP1, cIAP2, NAIP (NLR family, apoptosis inhibitory protein), living, ILP2 (IAP-like protein 2), BRUCE, or expression are 8 representatives of the relatives of inhibitors of apoptosis proteins (IAPs) that have been identified[2].

Breast cancer is one kind of tumor that over expresses the enzyme survivin, an inhibitor of apoptosis (IAP). Its key duties include preventing apoptosis or controlling mitosis, both of these are linked to the development of cancer. Given that protein expresses

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

differently in normal tissues or malignant tissues, it has emerged as a promising ligand for the initial identification or prognosis of melanoma. By furthermore, it is now clear that inhibiting survivin, either on its own and in conjunction with other methods, is a viable treatment strategy.

The protein called survivin, which inhibits apoptosis, is detected across a wide variety of cancers. The severity of the medical result with higher transcript rates of the gene is correlated. Survivin has emerged is a primary focus for both cancer diagnostics or predictive in addition to anti-cancer therapy due to its low expression in healthy tissues[3]. When survivin is overexpressed in malignancy, cell growth milestones can be bypassed, allowing altered cells to continue abnormally during mitosis. Throughout this review, the sequence of the survivin genome as well as proteins, its production or role in apoptotic, as well as its genetic variations are briefly discussed.

Considering that it is present in the majority of patient cancers as well as its capacity to elicit innate immunological reactions, expression may act like a global tumor target. Consequently, the potential treatment approach for malignancy seems arising: suppressing Survivin activity through different immunotherapy or genetic methods. Throughout this review, many biological elements of survivin would be covered, along with several strategies for inhibiting survivin in cancer tissues. SVN is crucial for cellular proliferating or mitotic in mature progenitor cells as well as during embryogenesis. This protein is a potential diagnostic for treatment or detection due to the facts because the majority of cancers allow defining it to encourage its development or spread[4]. Accordingly, a number of medical investigations are being conducted that evaluate their use as a predictive and therapeutic indicator regarding tumor growth as dissemination. SVN is being investigated as a diagnostic/prognostic marker for immunological or pro-inflammatory disorders in additional to their application in the detection of cancer.

It should be noted that just like Survivine is a sign for both autoimmune or cancer, it would be crucial to combine it with other diagnostic biomarkers to discriminate between carcinoma or inflammation illness.

Considering that it is highly expressed in most tumor forms but is virtually undetectable in body cells, Survivine is a prospective option for tumor treatment. Notwithstanding this encouraging finding, anti-SVN cancer medicines have proven sluggish to emerge, while significant advancement has been made. Numerous therapy modalities, spanning antagonists of tiny molecules towards monoclonal antibodies, had been investigated[5-6]. Low effectiveness or severe toxicity make the small molecule strategy difficult. SVN monoclonal antibodies, meanwhile, have demonstrated more potential, with notable effectiveness in mice experiments or carcinoma cell lines. Even though anti-SVN drug medical trials are still in their initial stages, there are some obvious indicators of effectiveness with clinically significant benefits for individuals.

There is still hope for anti-SVN chemotherapy may lead towards effective treatments considering the unique position that Survivine plays in human cancer. Nevertheless, instead of being used as a stand-alone treatment, it is most probably going to be included of a combination approach. These combinations will probably include a variety of TAA or transport methods, supplementary immunotherapeutic (like immunotherapy inhibitors), or small molecule medications like therapeutic drugs that are specifically aimed at tumor features[7]. Having a multi-agent strategy ought to provide efficiencies which reduce doses, lessen side effects, and enable treatment to be tailored to the patient's tumor.

This fact that many of the strategies addressed here are sophisticated procedures involving vivo therapies or / and involving collection, processing, or injection of patient - derived is a significant problem. These therapies are probably costly or hard to implement on a large basis. In this setting, simpler vaccination techniques using peptides or therapeutic proteins, like ROP-SVN, come out as more probable to be reliable or useful methods.

Based on the proportion of cells exhibiting distinctive nuclear and/or diffused cytoplasmic immunohistochemistry response, survivin positivity has been evaluated analysing and processing. At least five high-power fields with a resolution of 400 were examined for nuclear and/or cytoplasmic immunoreactivities, which were then categorised into the respective ranges: 0, 5% to 20%, 1, or >20%. The dominating patterns were utilised for grading since the labeling of tumours were diverse. Tumors with a score of zero and 1 were regarded as negatives, as well as a threshold level of >20% was used to determine a significant stained[8]. As per DAKO (Carpinteria, CA) guidelines, overall degree of HER2 immunoreactivity to tumour cellular membranes had been graded like generally described in the following: Any transmembrane signals in 10% of tumour cells, 10% mild partial membranes stain in >10% tumour cells, >10% medium through robust membrane positive in >10% cancerous cells, 10% any identifiable membranes signal in >10% tumour cells[9-10]. Cancer with a rating of 0 or 1 was classified as negative inside the current research, whereas those with a value of 2 and 3 were classified as positive. EGFR responsiveness was assessed using the same standards that survivin, with the exception of tumour cell surface and/or intracellular immunoreactivities.

II. BIOCHEMICAL FUNCTION

By interacting with the actions of caspase-3, caspase-7, and caspase-9, survivin prevents apoptosis whether completely or implicitly. The connection or

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

collaboration of survivin with hepatitis B interacting protein (HBXIP), Smac/diablo, AIF pathway, HSP90, c-IAP-1, HER-2/EGF, leptin/Stat3, or progesterone/P53 can also have a caspase-independent influence on apoptosis. This zinc interacting fold, called BIR and made up of around 60-70 amino acid residues, is present in 1-3 forms inside this enzymes produced by the IAP group and is crucial for the proapoptotic action of these proteins[11]. That gene for such 16.5 kDa specific protein as survivin, which is the tiniest component of the IAP group, is located on the extended arms of chromosome 17, inside the telomeric region 25. (17q25). The living beings survivin genome is roughly 14.7 kb in size and is translated from a GC-rich, TATA-less promoters to create a polypeptide of 142 amino acids[12]. Just one baculovirus IAP repeat (BIR) NH2-terminal modules as well as a -COOH terminus amphoteric helix coiled region makes up the physical characteristics of a survivin enzyme, in place of the traditional really interesting new gene (RING)- fingered region typical of all IAPs.

Research has been conducted to ascertain the fundamental molecular processes of survivin since it is highly expressed in a variety of malignancies in therapeutic settings. Survivin is a functionalized protein that suppresses apoptotic that is essential for cell proliferation at the cellular scale (Figure 1). Survivin may suppress apoptosis by interfering with caspases, potentially in the mitochondria portion rather than the cytosolic component, according to some theories[13-14]. Survivin has been shown to effectively bind to caspase-3 or caspase-7 with a submicromolar affinity inside a research employing surfaces plasmonic resonant spectrometry. Additionally, in electrophoresis experiments, myc-tagged survivin bound caspase-3 and caspase-7. Considering that survivin has just solitary baculoviral IAP repeat (BIR) region as well as the BIR motif has been demonstrated to be crucial in addressing caspases in other IAP family subgroups, the ability of survivin to obstruct caspase function is not unexpected.

Surprisingly, current research suggests that survivin could also obstruct caspase-free apoptosis. For instance, it has been shown that survivin prevents the apoptosis-inducing factor from being transported (AIF)[15]. AIF is a bound to the surface which is typically restricted in a mitochondria inner membrane, however when it global logistics towards the nuclei, it causes chromosomal constriction with cleavage of DNA into large molecule mass variants of >50 kb.

It's fascinating to note that AIF is translocated in different tumor cellular types when expression is down-regulated.

Survivin enhances cellular viability through addition to inhibiting simultaneous caspase-dependent or -independent apoptotic via interacting with microtubule pathways or cell cycle-related kinase (Figure 1). Survivin seems to control cellular proliferation like a component of the chromosomal passenger complex (CPC). Survivin had been demonstrated can interact to Borealin, INCENP, and Aurora-B kinase. Throughout mitotic, survivin moves from the spindles midzone to centrioles along such a para-polar path throughout prophase or mitotic phase, then vanishes at the conclusion of cytokinesis[16-17]. It had been demonstrated that over-expression of related genes inhibits unidirectional development the tubulin in midbodies throughout cytokinesis as well as microtubule dynamics instabilities within mitosis spinners or transcription factor microtubule nucleation. Furthermore, it has been demonstrated that internal trafficking of a polyclonal antibody to survivin causes spindle abnormalities as well as the development of multi - polar mitosis spindles. Furthermore, it has been hypothesised that survivin could also control the respiration of cancer cells (Figure 1). Findings from this work by Roca et al. showed that a phosphoinositide 3-kinase/Akt/survivin axis prevents conventional prostate cancer PC3 cells against autophagic cell death by CCL2 (Chemokine (C-C motif) ligand 2, MCP-1, monocyte chemo-attractant protein-1). When taken as it whole, survivin seems likely be a master molecule that controls several routes for longevity in cancerous cells[18-19].



Figure 1: Molecular functions of survivin

2.1 Survivin expression is regulated by phosphatidylinositol 3-kinase/AKT pathway of intracellular human epidermal growth factor receptor 2 signals.

The impacts with certain signaling inhibitor affecting the transcription of survivin are investigated through order to better understand the HER2 upregulating responsible for the modulation of survivin protein expression. After treating SKBR-3 cells for the specified amount of time using both PI3K inhibitor LY294002 and MEK1 inhibitor PD98059, concentrations of phosphoproteins or survivin were measured by Enzyme - linked immunosorbent assay. Following 6 hours of treatment, the PI3K inhibitor reduced the amount of survivin, although not the MEK1 antagonist[20]. However, both inhibitors were capable to lower the amounts of the corresponding subsequent phosphoproteins, pAKT and pERK (Fig. 2A - B). Depending on this data, decreasing that survivin protein concentration when the PI3K inhibitor is present requires more than two hours. Overall, it became clear that the

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

PI3K/AKT cascade for extracellular HER2 signaling of breast carcinoma cells might modulate its quantity of survivin proteins, at least partially.



Figure- 2 Effect of PI3K inhibitor or MEK1 inhibitor on the protein levels of signaling molecules and survivin in SKBR-3 cells. SKBR-3 cells were incubated with either PI3K inhibitor LY294002 (*A*) or MEK1 inhibitor PD98059 (*B*) for the indicated hours and levels of phosphoproteins and survivin were analyzed by Western blotting.

It has been demonstrated that Survivin, an IAP group representative that was first identified, may inhibit the action of caspases. Survivin had also being demonstrated to be crucial for cellular proliferation as well as the mitosis pathway. Survivin or livin have various tissue expression profiles from other IAP group components since they are only extensively expressed in particular tumour tissues as well as not throughout healthy adulthood tissues[21-22].

Numerous data demonstrate that the peptide had prognostic importance since it is correlated with poor clinical outcome or survivin activity through tumor tissue. Additionally, it contributes towards the chemotherapy resistance seen in some cancers. When survivin was over expressed, tumour cells were resilient to chemotherapy agents, and when it was under expressed, they became more sensitive. So, it was thought that survivin is the optimal biochemical focus for tumor treatment.

BIRC5/Survivin is an enzyme with multiple biological activities that controls apoptosis or mitotic effectively for either cancerous cells or embryo tissues throughout tumorigenesis and metastasis. However, the direct regulation of macroautophagy/autophagy by BIRC5 within organisms had not often proven demonstrated. Throughout cell cultures, ATG7 transcription as well as the development of the ATG12-ATG5-ATG16L1 combination was essential to accessory elongation during autophagy[23]. Inside this research, researchers found that during healthy mammary cells or tumour tissues, overall rates of transcriptional activation for BIRC5 or ATG7 are negatively linked, but the rates of BIRC5 with SQSTM1/p62 were favorably connected. Molecularly, researchers discovered that in human disease (MDA-MB-231, MCF7, or A549) as well as mouse embryonic fibroblast (MEF) tissues, BIRC5 directly attaches towards the ATG12-ATG5 conjugation that adversely regulates the protein level of ATG7, blocking a development of the ATG12-ATG5-ATG16L1 binding protein. For MDA-MB-231 or A549 cultures beneath serum-depleted circumstances, researchers similarly had seen the concomitant physical dissociation between BIRC5 with ATG12-ATG5 (but hardly CASP3/caspase-3) as well as an increase of autophagy[24-25]. Interestingly, researchers discovered that BIRC5 protects DNA integrity via autophagy negative-modulations in both human disease or MEF cell during non-stressed circumstances, throughout contrast to a commonly held belief because activation of starvation promotes DNA repairs for cell undergoing cellular stresses. Throughout summary, this research shows that BIRC5 has an unique function among cancerous cells like a primary controller of autophagy. In both cancerous and embryonic tissues, BIRC5 could function like a "bridging molecule" that controls that interaction among mitotic, death, or autophagy.

2.2. Among mice embryo fibroblasts cells or breast cancerous cells, BIRC5 inhibits autophagy.

Researchers have recently shown that lipid nanoparticles administration of an antisense BIRC5-expressing plasmid DNA boosted the development of LC3B-II conversions and LC3 puncta in human tumor cells, which are indicators of autophagosomes or autolysosomes. Inside this research, they first aimed to validate the impact of altered BIRC5 transcription on autophagy in cells from multiple anatomical sources with CASP3 expression levels[26-27]. Western blot assessment of the MDA-MB-231 (CASP3-expressing carcinoma cell line), MCF7 (CASP3-deficient mammary tumour cell line), A549 (CASP3-expressing cancerous cell line), as well as mouse embryonic fibroblast (MEF) cells revealed that BIRC5 downregulation by siRNA encouraged LC3B-II transformation as well as lowered SQSTM1 utterance (an autophagosome moiety) (Figure 3A and S1A).For MDA-MB-231 cells, BIRC5 knockdown significantly elevated the presence of LC3 puncta as well as acidic vesicular organelles (AVOs), like autolysosomes and/or lysosomes, and lowered the protein levels in SQSTM1 (a dynamical biomarker for autophagosome flux activation) (Figure S1B or S1C, Figure 3B). Additionally, the mRFP-EGFP-LC3 wanting to convey MDA-MB-231 cell lines handled to BIRC5 siRNA produced more yellow (representing autophagosomes) as well as red fluorescent (representing autolysosomes) LC3 puncta (Figure 3C), or the transformation of LC3B-II has been further expanded in cells co-treated with BIRC5 siRNA as well as CQ (Figure S1D), confirming the notion that BIRC5 knockdown tends to increase autophag. Contrarily, in the treated cells, ectopic transcription of BIRC5 boosted its

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

transcription-independent SQSTM1 transcript while decreasing LC3B-II conversions (Figure 3D,E). ATG7 is a protein that is recognized to be crucial in the production of autophagosomes during classical autophagy, while resveratrol is a lysosomal inducer. The impacts of resveratrol on LC3B-II converting[28], SQSTM1 or ATG7 transcription, LC3 puncta, as well as AVOs production in MDA-MB-231 cells were lessened by ectopic accumulation of BIRC5, according to the findings of the western blot analysis with microscopy (Figure 3F-H). Additionally, inside recombinant mRFP-EGFP-LC3-expressing MDA-MB-231 cells, overexpression of BIRC5 reduced its impact of resveratrol just on development of the yellow (greenish-yellow) or red fluorescent LC3 puncta, demonstrating that BIRC5 translation suppresses autophagosome flow in molecules (Figure 3).



Figure 3: BIRC5 downregulation induces autophagy-dependent DNA damage in human.

Cancerous cells' autophagy is regulated by BIRC5. (A) At 48 - 72 hours, either scrambled siRNA and BIRC5 siRNA was injected into cancerous cells. Western blotting is used to identify the activity of various enzymes. Internal control is accomplished with ACTA1/actin. (B) BIRC5 siRNA or scrambled siRNA are injected into MDA-MB-231 fibroblasts for the times specified. MDC was used to dye the cells, then electron microscopy is used to detect if AVOs had formed. These symbols "**" (p 0.01) and "***" (p 0.001) indicate a significantly meaningful variation for these number the AVOs expressed inside cells among the experimental groupings. (C) Over such times specified, scrambled siRNA and BIRC5 siRNA are injected into MDA-MB-231 cells that have been generating a mRFP-EGFP-LC3 protein (from the plasmid DNA, ptfLLC3). Fluorescence imaging is used to detect the development of green or red fluorescent LC3 parenchyma. The "merged-pictures" of the green as well as red fluorescent photographs are demonstrated in each pane[29-30]. (D) Either pCMV6-XL4 plasmid DNA (Empty plasmid) or even the pCMV6-XL4-BIRC5 plasmid (O/E BIRC5; O/E - ectopic expression) are injected into MDA-MB-231 or MCF7 cells for 72 hours. Western blotting is used to identify the activity of various enzymes. An external controller is implemented using ACTA1. (E) Cells were transplanted over 72 hours using both the empty plasmids and pCMV6-XL4-BIRC5 plasmids that expresses BIRC5. qPCR has been used for estimate that comparative abundance of SQSTM1 mRNA transcripts inside these tissues. No statistically significant variation exists between the experimental sets, as shown by a "N.S." (F and G) MDA-MB-231 cells were transplanted over 48-hours with either the vacant plasmid DNA or the pCMV6-XL4-BIRC5 plasmid DNA that expresses BIRC5[31]. Western blotting and fluorescence microscopy were used to analyse the transcription of various proteins as well as the development of Caspase-3 puncta, accordingly. (H) Cells were stained with MDC, then fluorescent microscopy is employed to detect if AVOs had formed. "***" (p 0.001) indicates the significantly meaningful variation in the number if AVOs contained within cellular among the experimental groupings. (I) Resveratrol was given and withheld from the MDA-MB-231 cells that expressed mRFP-EGFP-LC3 for 48 hours. Fluorescent imaging has been used to detect the production of green as well as red luminous LC3 parenchyma. The "merged-pictures" of the green as well as red fluorescence pictures have been demonstrated in each panel. Compare values: 25 mm, 30 mm (B, G, and H) (C and I).

\The connection among BIRC5 affirmation as well as the initial concentration of autophagy has been then investigated in medical specimens through utilising immune-histochemistry assessment to determine the utterance of BIRC5, ATG7, as well as SQSTM1 on segments of breast carcinoma (n = 30) as well as the corresponding regular mammary glands (n = 30) (tissue array; SUPER BIO CHIPS - CBB3)[32-33]. This ATG12-ATG5-ATG16L complexes as well as the influence occurs of LC3 (i.e., LC3B-II conversion) need the conjugated of ATG12 with ATG5 (Figure 3A), which would be facilitated by the E1-like enzymes ATG7 in cell cultures. Overall over expressed transcript concentrations of BIRC5 with ATG7 have been negatively linked, but the production values of BIRC5 with SQSTM1 were highly associated between regular

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

breast cells or cancerous as well as regular, supporting their hypothesis that BIRC5 has a detrimental reports submitted on respiration (Figure 3B-D). Together, these findings lend credence to the idea that BIRC5 inhibits autophagy.A

ccording to research, 60% to 80% of breast cancers display survivin. These findings, which nearly agreed with earlier research, demonstrated that there was no distinction among invasive ductal carcinoma or aggressive medullary cancer with terms of related genes positive[34-35]. In additional to being expressed inside a range of tumour cells with different histological subtypes, survivin also has a definite cell cycle-dependent expression during mitotic. Cell cycle elements/cell cycle genes homologous section regions, which are situated in the distal survivin promoters, are involved in this process are predominantly regulated at the transcriptional regulation. Numerous regulating elements have been identified so far, notably nuclear factor-B (NF-B), Sp-1, T-cell factors[36], or Ha-ras as positive regulating elements or p53 progestin, IFN-responsive factor-1, as well as neuroblastoma nutrients complexes as negative signaling pathways. This ubiquitin/proteasome-mediated proteins breakdown pathway controls survivin protein content in additional to transcription modulation.

III. DIAGNOSIS AND DETECTION OF DISEASES

Despite those with slightly negative lymphatic glands, between 30% - 50% of individuals having initial prostate carcinoma still have recurring illness, that is often distant. Individuals who get neoadjuvant chemotherapy (NACT) have a terrible prognosis of 10-20% 5-year mortality since 10%-35% of them may not react favorably due to cisplatin resistance. Breast cancer presents a significant difficulty since the long-term outlook is often poor. There is growing indication that initial primary tumors release cancer cells into the bloodstream[37]. Therefore, its identification of migrating cancer cells was done using the clotting factors of mammary carcinoma sufferers (CTCs).

Currently, a variety of tumor biomarkers have been identified with varied levels both sensitivity as well as specificity, including cytokeratin, mammaglobin, c-Met, maspin, epidermal growth factor receptor (EGFR), Her2/neu, transmembrane associated mucin1 (MUC1), or CD44. Additional categorization of mammary carcinoma individuals is still difficult since the majority on such criteria become less accurate in tiny tumors[38].

Survivin is only produced in cancerous tissues, so since it may prevent apoptosis, increase cell proliferation, or improve vasculature, its presence in bodily fluids may be a useful tumor marker for early identification as well as diagnosis (table-1). A RT-PCR Immunoassay approach was used through this work by Yie et al to identify survivin-expressing migrating mammary tumor lymphocytes inside the periphery circulation. (50.7%) out of 67 breast cancer individuals had circulating cancerous cells which expressed the survival protein, but not the healthy women who served as standards[39-40]. It has been discovered that a number of clinic pathological factors, including vessel intrusion, histopathology, tumor size, nodal participation, ER/PgR prestige, Her-2 expression, as well as diagnostic phases of the illness, are strongly correlated with the existence of transmitting carcinoma cells that convey survivin. The researchers came to their conclusion that identifying tumor entities in the blood that are expressing survivin mRNA might be useful for identifying breast cancer metastases or recurrences.

Table 1: Survivin for breast cancer diagnosis and detection

Alone or combined	Assay	Collection	Conclusions
alone	RT-PCR 37/41 (90.2%)	specimen	a useful diagnostic marker for breast cancer.
with c-erbB2 and PLU-1	RT-PCR27/39 (69.2%)	specimen	useful as a marker for diagnosis
alone	RT-PCR ELISA	PB	PPV in vessel infiltration, histological grade, tumor size, nodal status, ER/PgR status, Her-2 status and clinical stages
with PTTG1, UbcH10 and TK1	membrane array technique	PB	PPV in tumor size, histologic grade, lymph node metastasis and TNM stage
alone	EIA and ELISA	Serum and urine	serum survivin level could be a sensitive marker for detecting metastases in lymph nodes
with hTERT and hMAM	real-time q PCR	PB	PPV in TNM stage, and lymph node metastasis

ELISA is for enzyme-linked immunoassay test;
PPV- Stands for positive predictive value;
NPV- Stands for negative predictive value;
PB- Stands for peripheral blood.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

Similarly to such results, Chen et al used a membranes mosaic approach to investigate the genes transcription inside the combined manner. One of the four indicator genes found in migrating tumor cells throughout the plasma of Taiwanese women with breast cancer was identified as surviving[41]. The findings showed that the presence of several proteins, particularly survivin, was substantially linked with tumor size, histopathological grading, lymphatic nodal metastases, and TNM phase. Throughout order to better understand the concentrations of survivin in individuals with breast cancer including their links to known prognosis or treatment, Guney N. undertook a research. Their findings revealed that serum survivin levels might serve as a reliable diagnostic for spotting metastasis in mammary carcinoma sufferers' lymph glands[42-43]. Most lately, a research from China described how finding survivin or another linked gene could help with breast cancer diagnosis and give an initial indicator of highly malignant activity prior to the development of metastatic disease. When contrasted to a solitary marker test, several biomarker tests can greatly increase the accuracy of identifying heterogeneity tumor cells. Additional medical trials are required for more dependable findings.

IV. SURVIVINE AS A DIAGNOSTIC FOR DEVELOPING TUMOURS

Throughout sick people with a variety of tumor types, such as glioma, breast cancer, cervical squamous cell carcinoma (CSCC), acute myeloid leukaemia (AML), gallbladder cancers (GBC), renal cell carcinomas (RCC), disperse stromal cells tumors, as well as dissipate large B-cell lymphoma, upregulated SVN is associated with tumor growth or a poor diagnosis[44].

In all of these investigations, there had been a substantial correlation between SVN upregulation (mRNA and/or protein) with progressed tumor phase, poor tumor diversification, or poor overall mortality. Additionally, overall categorization of tumor subgroups and the subcellular localization of SVN are connected[45]. SVN's ability to be used as acoustic screening tool had been studied in many clinical trials. For instance, urinary SVN mRNA was examined under like a significant diagnostic sign for bladder cancer. WT-1 or HPV16 E7 were also employed in Survivine for the evaluation of certain immune function.

SVN expression has shown to be a valuable biomarker of hyperplasia in situations like prostatitis proliferation, colon polyps, endometrial polyps, ormesenchymal hypertrophy because accumulation of SVN stimulates aberrant cellular proliferation."

4.1. SVN as a metastatic diagnostic

Nearly all tumors produce SVN. Elevated concentrations of SVN affirmation have a number of unfavorable effects on tumor advancement as well as development, such as the promotion of membrane proliferation,, apoptosis inhibition, inductive reasoning of tumor endothelial angiogenic, as well as decreased responsiveness of cancerous cells to chemotherapy and radiation therapy[46]. Several outcomes work together to promote tumor dissemination. Investigation has demonstrated that breast tumor stem cells harboring an SVN gene deletion decreased their invasive characteristics or experienced death. Survivine transcript concentrations are related to lymphatic nodal metastases in colorectal cancer. Moreover, siRNA-mediated SVN knockdown substantially reduces clonogenicity, migration, as well as incursion, repressing tumor growth as well as lymph node metastasis in a mouse model of colorectal cancer, while pituitary plexiform squamous cell tissue samples with high SVN affirmation were found to have distant metastasis lymphadenopathy cells[47].

As a result, there is significant support across several trials with various tumor kinds showing a substantial favorable connection between SVN transcriptions with metastatic spread, indicating this SVN could be a viable diagnostic to track overall development of malignancies.

4.2. SVN as a biomarker for inflammation or immunological disorders

SVN is upregulated in immunological or inflammation illnesses in contrast to cancer. In inflammatory illness, SVN overexpression boosts the generation of antibodies or cytokines while preventing death of innate immune lymphocytes. Numerous immunological or inflammation conditions, such as rheumatoid arthritis (RA), myasthenia gravis (MG), systemic lupus erythematosus (SLE), multiple sclerosis (MS), inflammatory bowel disease (IBD), or systemic sclerosis, had been associated with high SVN levels (SSc). In SVN was evaluated as a predictive biomarker for joint damage in people with existing rheumatoid arthritis (RA) as well as a diagnostic in assessing the probability of acquiring rheumatoid arthritis (RA)[48]. The findings demonstrate that serum SVN testing, in addition with various medical complaints or immunological measures, is useful in identifying individuals who might advance from arthralgia to complete RA. For evaluate the therapy responsiveness for RA, SVN was investigated in plasma like a potential complement diagnosis.

4.3. SVN test in combination with other biomarkers

SVN is not the only bioactive compound that has been widely employed as an indicator for cancer diagnosis or prognostic. Molecular apocrine breast cancer (MABC), VEGF, carcinogenic BRAF mutations, or KRAS mutants in pancreatic are a few well-known instances.

An SVN test must be combined with additional indicators during tumor detection since SVN is similarly increased in autoimmune or inflammatory. For instance, measuring SVN or VEGF concentrations improves the precision of passive diagnostics[49]. Detection of both SVN and EGFR is helpful in the identification of triple-

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

negative breast carcinoma, whereas simultaneous amplification of SVN or VEGF in peripheral circulation is a useful prognostic sign among individuals with epithelial adenoid carcinoma of the laryngeal (TNBC). Among individuals with colorectal carcinoma, the combination activation of Aldh1, SVN, or EpCAM is a predictive factor for prognosis or tumor relapse. Inside an initially expected for auto-antibodies linked to malignancy through generally or small-cell lung illness in specific, SVN is expected to be utilised like a diagnostic with p53 or cMyc[50]. In summary, SVN is a biomarker for malignancy or inflammation illness that may be beneficial in identifying phase or danger of advancement. In order to increase the specificities or sensitivities of such assays, it is probably to be employed in conjunction with additional markers."

V. SURVIVIN AND TREATMENT OF DISEASE

Individuals with advanced prostate cancers have a substantial hurdle related to tolerance to anti - androgen treatment, that if resolved might result in considerable improvements in the management of these individuals. Prostate cancer's hormonal tolerance is partly caused by the activation of antiapoptotic proteins following androgen deprivation. Humans hypothesised that Survivin, a current recruit of the inhibitor of apoptosis (IAP) family, continues to perform a possibly significant position in oestrogen treatment opposition as well as that attacking Survivin could improve responsiveness to antiandrogen treatment through bladder cancer only in light of the mounting substantiation that Survivin is affiliated to both tumor growth as well as antibiotic resistance[51-52]. Qualitative Western examination was used to examine the levels of Survivin transcription inside the 3 prostate carcinoma cell types LNCaP, PC-3, or DU-145. Survivin was discovered to be significantly expressed across the 3 cellular lines. It was shown that testosterone treatment with 5-dihydrotestosterone (DHT) boosted Survivin transcription in Cells transfected having functional androgen receptors (ARs). Flutamide therapy, on the other hand, reduced Survivin transcription in LNCaP cells. The physiological impact of Survivin on susceptibility to Flutamide was the subject of this subsequent research. Following infection with recompilation adenoviruses expressing either wild-type Survivin pAd-S(WT) or a dominant-negative mutation of Survivin Thr34 Ala pAd-S(T34A), these LNCaP cells were subsequently given Flutamide[53]. Apoptosis or cell growth was measured in vivo or on vitro, respectively. Depending upon these tests, it was shown that Survivin may promote tolerance to various antis - androgen therapy. This was discovered that external insulin-like growth factor-1 (IGF-1), a recognised activator of AKT signalling, might keep increasing Survivin interpretation as well as outcome in pan-cell cycle affirmation perhaps in AR-negative testicular tumour molecule segments PC-3 as well as DU-145[54]. The researchers also discovered that straightforward testosterone enhancement occurred through pan-cell cycle affirmation of Survivin, which has been discovered to be facilitated by AKT. Researchers then looked into whether Survivin-mediated stimulation by IGF-1 through AKT may promote resilience to antiandrogen treatment in light of this alternate method of Survivin production with recent results showing Survivin might promote resistant towards Flutamide medication. It was shown to be true both in vitro as through the vivo, suggesting an unique mechanism of resistance to antiandrogen treatment. According to this research, IGF-1 signaling-induced overexpression of Survivin provides tolerance to Furosemide in prostate carcinoma cells[55]. A unique method to increase responsiveness to testosterone elimination treatment is revealed by the specific suppression of Survivin, which seems to augment overall curative potential with Furosemide through vitro as well as in vivo.

5.1 pharmacological strategies that target Survivin

The pharmacological blockage of Survivin in tumors could potentially result inside a progressive advantage owing to the significant function for Survivin in tumor cell proliferation, apoptotic, chemotherapeutic tolerance, or tumorigenic viability. Different methods have been considered to prevent Survivin from being expressed and functioning in tumor cells.

(i) Methods used in immunotherapy to provoke an autoimmune reaction to Survivin,

(ii) Specific molecular inhibitors or antagonism that prevent Survivin activity

(iii) Methods relying on nucleic acids that block the transcription of the Survivin genes or

(iv) Survivin genetic deletion is used to control apoptotic as well as the cell cycle.

5.2 Carcinoma therapy using survivin as a target

As a controller of simultaneous cell division and apoptotic, Survivin has a prominent place amongst IAPs. Normally developed cells, meanwhile, express survivin extremely weakly and not at all. Does cellular functioning or fewer cell division/apoptosis of immune tissues correlate in some way with low and no Survivin expression?

Embryogenesis mortality, a lack of self-renewing bone marrow neural stem cells, or bone marrow elimination are all seen in Survivin knockdown. The growth stop in T-lymphocytes during the dual negatives phases and the retention of young T cells in the peripheral are caused by the selective ablation of Survivin in the hypothalamus[56]. Survivin also seems to play a crucial role in the development of acquisition is a process or megakaryocytes, initial B cell progenitors' proliferation, or stimulated adult B cells. Since Survivin seems to be an interesting protein that controls the actions of different immune cells, treatment strategies

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

that target Expression must be thoroughly considered.

5.3 Survivin based Immunotherapeutic approaches

Immunology was the process of influencing the body's immune systems to launch an anti-tumor reaction. William Coley became the earliest to use this theory, treating sarcomas using extracts of Streptococcus pyogenes or heat-killed Bacillus prodigious (formerly designated as Serratiamarcecsens) bacteria.

According to Coley's research, the immune expansionary elements in "Coley's poisons" increased the anti-tumor immune response that caused malignancy to remit. The findings of Coley's experiments drew heavy criticism, and the idea of immunotherapeutic as a successful method of treating cancer is completely rejected. Chemotherapeutic or radiation, two possible tumor treatment techniques which were by that point fully established, seemed to have the downside of causing cancer relapse or toxicity[57].

Furthermore, it became clear that the immune system played a critical role in regulating specific forms of cancer as the fundamentals of immunotherapy were better understood. Immunotherapy is a more effective treatment alternative than chemotherapeutic or radiation since it is targeted for tumor cells that have no adverse effects, according to several immunological concepts that have been uncovered.

Through the induction of/improvement of the anti-tumor immune response or the reversal of inhibitory immunological transmission, chemotherapy destroys tumor cells. Through the use of particular cancer antigens or even by ex vivo growth of executioner cells or their subsequent injection again into the sufferer, effective chemotherapy entails to creation of a tailored anti-tumor inflammatory system in the recipient. Transfer of already-formed components, such as monoclonal drugs or T cells that target a particular antigen, is referred to as passive immunotherapy[58].

It was effective to convert a number of monoclonal targeting growth factor receptors or immunological markers on cancerous cells for medicinal use in a variety of malignancies. The emphasis on inhibiting proteins in immunological intercellular communication towards a positive anti-tumor reaction is once again changed in reaction to the current performance of inhibitors addressing regulatory immunological regulators like CTLA-4 and PD-1.

The therapeutic transcription of antigen-specific tumor vaccinations has not been as effective as passively immunotherapeutic, despite the fact that a variety of cancer monoclonal antibody vaccine methods have demonstrated high responsiveness in medical tests[59]. Targeting particular tumor antigens like a vaccine contender, causing vigorous innate immunity, mainly via DCs, or inducing cytotoxic T cell (CTL) responses are the main goals of cancer vaccines.

Antigen-presenting cells (APCs) deliver the MHC-peptide combination towards Immune cells during stimulation after processing tumor antigens into peptide or loading them into MHC proteins. Antigen-specific T cells are initially stimulated in the peripheral lymphoid tissues by interacting with APC; this is the initial step in the successive activation of effector T cell responsiveness. Dendritic cells (DC), in specifically APCs, collect antigens from tumor cells and offer these to CD4+ T cells through the MHC class-II route or to CD8+ T cells through crossover presenting or pass primed[60-61]. It takes more than just antigen identification and MHC to efficiently stimulate T cells; other co from APC controls the range of T-cell activation. The so-called "Immune checkpoints"—stimulatory or inhibiting molecules—can trigger these many co-signals. After being prepared through APCs, antigen-specific T lymphocytes would search for the appropriate MHC peptide on targeted tumor cells or carry out cell lysis. Utilizing particular cancer antigens in chemotherapy increases the number of T cells that are particular for that target, preventing tumor immune evasion (Fig. 2). The vaccination tactics include DNA vaccines, cytokine and co-stimulation boosted vaccines, dead tumor cells, or DCs injected with proteins and peptides. They also include synthetic viruses expressing target antigens or other synthetic organisms[62]. Utilizing a potent adjuvant improves the expression of tumor antigens as activates immunological effectors pathways, inducing a potent CTL reaction to tumor cells.

Cancer immunotherapy research and clinical symptoms occur when tumor self-defense outweighs anti-tumor antibodies. The several immunotherapy strategies are used to correct this mismatch.



Figure 2: Survivin: a unique target for tumor therapy | Cancer Cell International

The optimal antigens for a cancer vaccination are one that is particular that is highly expressed on tumor cells. Due to its unique distribution within tumors or crucial function on controlling tumor cellular proliferation or death, survivin has surfaced as an attractive target in therapeutic antibodies. Survivin is the fourth highest abundantly produced gene in individual cancer cells, according to an examination of the human genome. Neuroblastoma, melanoma, or non-melanoma melanomas as well as colorectal or bladder tumors have all shown linked to amplification of Survivin as well as a poor prognosis[63]. As was already mentioned inside the review, survivin amplification also results for a rise of chemotherapy treatment resistance. The overexpression

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

of survivin gives tumor cells a selective advantage, so it may be used as a global pharmacological or diagnostics focus for all tumor types.

During recent years, monoclonal antibodies for malignancy have showed significant promise. Any approach for targeting a TAA like SVN must combine both antibody- and T cell-based immunotherapy if the TAA (SVN) is produced on the exterior of tumor cells. Vaccines, adaptive dendritic cell (DCs, antigen presenting cells) driven vaccinations[64], or combining of other monoclonal antibodies are the forms of SVN immunotherapeutic now being employed in medical tests.

Although SVN transcription on tumor cell surfaces has been shown in multiple papers, antibody-based anti-SVN immunotherapeutic (particularly CAR-T treatment) have not yet been tested in human research.

The T cell-based vaccinations against SVN, the DC-based vaccinations, or combinations therapy are discussed in the next subcategories.

VI. DIFFERENT ROLES OF SURVIVIN HORMONE

Enhancement of angiogenesis in cancerous cells is one of the routes involved in Survivin-mediated tumor growth. By still processes, survivin increases VEGF expression or encourages endothelial cell (EC) growth. It was hypothesized that a positive reinforcement loop connects the production of Survivin in tumor cells to PI3K/Akt increased -catenin-Tcf/Lef-dependent transcriptional that causes the release of VEGF for vasculature.

Endothelial dysfunction in glioma has been found to just being inhibited by Survivin suppression[65]. In vivo breast and cervical cancer xenograft models, suppression of Survivin through small interfering RNA (siRNA) sensitized individual cancerous cellular to apoptotic as well as reduced tumor growth and vasculature. By encouraging the assembly of glucan into separate fibers, product is known VEGF production also helps to chemo-resistance.

Comparing with regular organs, tumor vascular ECs have unusually high levels of survivin, which makes them more resistant to drugs. Targeting Survivin in a tumor would thus encourage not just the demise the cancerous cell and also make cells within the tumor vascular system more sensitive to chemotherapeutics.

Survivin could work with other IAP participants to encourage metastases. Human melanomas or cancer cells may migrate more readily when Survivin is overexpressed on collagen, but Survivin reduction in sub-apoptotic circumstances prevents this.

In a mouse prostate cancer mouse as well as a rat insulinoma, an intermolecular connection involving XIAP with Survivin increased tumor cells penetration in vitro or metastasis spread in vivo. That route functioned regardless of how important IAPs are for cell survival. Like a result of signaling pathways along such a path that leads, NF-B was activated, fibronectin's reproduction was increased, 1 integrins sent autocrine as well as paracrine signals, but also cell motility kinases FAK or Src were constitutively phosphorylated, suggesting that IAPs were directly involved in helping to promote metastasis. Equally important, signal transmission via this route caused tumor cells to produce the collagen genes several times more than normal but could not cause the typical epithelial-mesenchymal transition (EMT)[66]. By the overexpression of integrins, survivin has also been demonstrated to promote melanoma cell metastasis. Survivin collaborated alongside vascular endothelial growth factor-C (VEGF-C) to increase the lymphatic spread of breast cancer. Numerous individual investigations have also shown the correlation between enhanced tumor invasion or metastasis by survivin amplification, suggesting that survivin has a purpose other than controlling the apoptotic or cell proliferation of carcinoma cells.

VII. PRODUCTION OF SURVIVIN HORMONE

The IAP group of inhibitors of apoptosis (IAP) includes survivin. Like a result of the survivin molecule's ability to prevent protease function, apoptosis, or regulated cell damage, is negatively regulated. It has been demonstrated through interruption of the mechanisms that induce survivin, which increases apoptosis or slows tumor formation. Just the G2-M stage of cellular cycles results in the production of the survival protein. By interacting with filament during mitosis, survival localises to a spindle apparatus or could help control the process[67]. Anti survivin medication represents a promising disease therapeutic option since survivin is abundantly prevalent in the majority of malignancies also linked to chemoresistance, tumor progression recurrence, and decreased survival of patients.

A cell growth gene called Survivin (BIRC5), which is abundantly expressed in endometrial cancer, had been linked to a physiological role in healthy endometrium functioning. RNA from healthy cycling women were extracted throughout the proliferation or secretion stages of the menstruation in order to examine if the transcription of the survivin genes is influenced by reproduction androgens inside the female endometrium. Additionally, RNA was extracted from 21 endometrial biopsies taken from premenopausal women, both at the beginning on therapy by progestin propionate or 3 months afterwards.

Subsequently, RNA was extracted from endometrium specimens taken at baseline or six months after converted equine therapeutic efficacy in ten healthy menopausal women who were taking participate in an oestrogen substitution therapeutic medical trial. The level of gene regulation for survivin, insulin-like growth

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

factor binding protein 1 (IGFBP1), Ki67, or IGF1 were assessed by quantification RT-PCR research. Survival genes exhibited a statistical substantial 4-fold increase of transcription after prolonged oestrogen therapy, which was significantly connected with enhanced Ki67, a proliferative biomarker[68]. Survivin genetic variation is greatest inside the proliferation stage of the menstruation cycle.

Inside the human endometrial after prolonged progesterone therapy, survival genetic variation reduced 4–6-fold. Such findings imply that estrogens or progestogen control survivin transcripts inside the human endometrial of disease-free women. Survivin transcript could be utilised as a biomarkers of the effectiveness of oestrogen or progesterone therapy, based on the results, but more research is needed to confirm this idea.

7.1 Real-time quantitative RT-PCR

Each and every TaqMan quantification real-time RT-PCR (QPCR) test was created using Primer Express. The Statistical Genomic Research Lab created the tests or finished the procedures (UT-Houston Medical School, Houston, TX, USA). Like originally mentioned, 40 nanograms of RNA from each specimen were measured in triplicate along with a fourth reversed transcription zone of inhibition. SDS 1.9.1 software (Applied Biosystems, Carlsbad, CA, USA) was used to evaluate the findings with SuperROX (BioSearch, Novato, CA, USA) used as a standard marker[69]. Transcribed were measured in relation to a reference curves made up of 5 sequential logarithmic serial dilution of a known amount of DNA. The housekeeper gene's 18s rRNA transcripts level was used to standardise the average transcripts amounts for the experiments. The average ratio of (transcript/18s rRNA) is used to illustrate the information.

The following combinations for the survivin or 18s assays have been published (Nabilsi et al. 2009): Insulin-like growth factor binding protein 1 (IGFBP1; NM_000596): 620+GGGACGCCATCAG-TACC, 681–CCATTTTTTGATGTTGGTGAC, 638+FAM-ATGATGGCTCGAAGGCTCTCCA-BHQ1; IGF1 (M27544): 187+TCCAACCCAATTATTTAAGTGCT-GC, 278–ACAGCGCCAGGTAGAAGAGA, 227+FAM-AAGGTGAAGATGCACACCATGTCCTCCTC-BHQ1; Ki67 (NM_002417): 3323+AAGTTCACACGGACGT-CAG, 3391–GATGCTCTTGCCATCTCC, 3347+FAM-ACCACGCACACGCACAGAGAG-BHQ1."

7.2 Human endometrial that is cyclic has variable expression of the survivalin mRNA.

E2 or P4 signals, however, were dominant throughout its proliferation or secretion stages of the breeding process inside the mammalian endometrial. Earlier studies just on activation of a survivin gene inside the cycling individual endometrial have produced inconsistent results. Using RNA obtained from proliferative (n = 7) or secretory (n = 5) stage endometrial biopsy, QPCR testing was used to ascertain whether the survivin gene is actually transcribed inside the cyclic human endometrium[70]. Cell proliferation endometrium samples showed almost 50-fold greater levels of survivin gene activity than secretion ones (median proliferative=4•08, median secretory=0•08; P=0•01; Figure 3).

Researchers proposed that survivin transcripts concentrations are raised in reaction to E2 or lowered in reaction with P4 inside a human endometrial because distinctions among these 2 stages are primarily regulated by steroidogenesissignalling.



Figure 3: Sex hormone regulation of survivin gene expression in: Journal of Endocrinology

Human endometrial that cycles has variable expression of the survivalin mRNA. The presence of survivin was determined by QPCR using RNA specimens collected from endometrium biopsies of women who were either in the proliferation stage (n = 7) or secretion stage (n = 5) of the breeding process[71]. The median ratio of the data is (survivin/18s rRNA)106. Box indicates a dispersion of 25-75%, whereas scallops indicate a range of 10–90%. The significant level is assessed using the Mann-Whitney unpaired U test.

7.3 The human endometrium responds to oestrogen therapy by producing more survivin.

A substantial 4-fold up-regulation of the survivin transcripts was seen from endometrial samples following therapy with estrogens for 6 months (median pre=0•65, median post=3•23, n=10, P=0•013; Fig. 5a). 7 out of 10 sufferers had enhanced gene transcription transcription, whereas the remaining 3 individuals (#2, #5, and #9; Fig. 5b) either showed zero changes and a slight reduction in gene transcription interpretation. Researchers evaluated the transcriptome of IGF1, a well-known hormonally gene implicated in estrogen-mediated myometrial emergence, that humans have initially demonstrated to be stimulated by therapeutic efficacy in the epididymis of post - menopausal women. This measurement allowed us to verify the initiation of estrogen-regulated gene mutations in the women's endometrial lining after diagnosis.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

Researchers assessed transcriptase of nuclear antigen Ki67, a common proliferative biomarker, and verify whether the women reacted to hormone replacement[72-73]. They found that only 9 out of 10 individuals reacted with a proliferation phenotype as seen by enhanced Ki67 activity, despite this fact that all 10 of the post-treatment endometrial cells showed estrogen stimulation of IGF1 (Fig. 5d).

Significantly, individual #9 had a drop in the gene transcription transcripts as addition to the reduction in the Ki67 transcripts (Fig. 5f). However, IGF1 fold change (P=0•76, r2=0•12) and IGF1 folding change (P=0•758, r2=0•11) could not substantially interact with the mean difference in survivin initiation (P0•0001, r2=0•98) or the folds variation in Ki67[74]. The folds variation of gene transcription transcription was neither correlated to the female's ages (P=0•73), BMI (P=0•89), time from last menstruation (P=0•94), serum levels E2 (P=0•87), FSH (P=0•47), or prolactin (P=0•97) levels."



Figure 5: Sex hormone regulation of survivin gene expression

Following oestrogen therapy, the human endometrial expresses more survivin mRNA. RNA specimens from 10 women's endometrial biopsies were examined by QPCR for the presence of the proteins survivin (a or b), IGF1 (c or d), as well as Ki67 (e and f). For each individual after therapy comparing to pretreatment, the information is shown like a average proportion of (transcript/18s rRNA) (a, c, or e) or fold changes (b, d, and f). Box shows a range of 25-75%, whereas whisker covers a range of 10–90%. The statistical relevance is assessed using the Wilcoxon signed-rank test[75].

VIII. CONCLUSION

Survivin is presently widely employed in the detection, prognostic, or therapy of breast carcinoma due to its roles as a tumor gene/protein. It appears that immunochemistry and RTPCR measurement in serum/urinary survivin was an effective technique for identifying either initially detected or recurring prostate cancer. An unfavourable prognostic sign associated with worse survival rates in breast tumors was elevated survivin over expression among malignancy individuals. Among individuals having aggressive cancer, survivin expression could be a determinant for predicting how well they would respond to radiation or medication. Diverse techniques, including immunotherapies as well as small-molecule inhibitors, have been used to address survivalin as malignancy therapeutic targets. Despite some contradictory results, the majority of evidence suggests the measuring survivin expression may aid in the earlier detection, prognosis, or therapeutic evaluation of breast cancer.

Less or even no harm is caused to healthy tissue or cells when it is targeted for tumor therapy. The promise of survivin for diagnosis, prognosis, or prediction needs really be verified in substantial prospective trials. The tests used to assess survivin as well as its splice variations should also be streamlined, standardized, or subjected to external quality control systems evaluation.

Survivin has a variety of functions that influence cancer cell viability as well as the development of anti-drug reactions. Unfortunately, since there are now just a few survivin antagonists on the market, the discovery of therapeutically useful survivin antagonists may not follow the growth of survivin genetics over the last ten years.

Consequently, additional research into the survivin-specific smaller molecular inhibitor is necessary and could be essential for the creation of cancer therapies in the future.

On the contrary hand, tumors which produce survivin might well be treated alternatively using optimized survivin-targeting bimolecular. Given that survivin has various functions in various organelles in cancer cells, organelle transduction domain (PTD)-mediated surviving specific complex molecular treatment could be advantageous in prospective therapeutic situations when combined with various organelle-specific chemotherapeutic substances. For the development of more effective survivin-targeted therapies, more funding or research are required.

Throughout this paper, researchers demonstrate for the first time that this Survivin splice variation pattern, which they also describe in carcinoma cells, is mimicked in the serum of women with breast cancer by the Survivin splice variations. Regarding preclinical female carcinoma survivors, transcription patterns of exosomal-Survivin, especially Survivin-2B, can act as a

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

diagnostics and/or predictive biomarker, or "liquid biopsy," if they would. Additionally, a deeper comprehension of the function of this well-known proapoptotic cascade may aid in the creation of possible treatments for women with breast cancer.

Both in vitro and in vivo, siRNA targeting survivin greatly reduced the development of LNCaP or PC3 cellular tumors. 1,25D slowed down cellular division or lowered survivin genes transcription in LNCaP or PC3 cell. On the contrary hand, DU145 individuals' survivin genetic variation or growth and differentiation were unaffected. Additionally, a 1,25D decrease in cellular growth after the insertion of siRNA against the DU145 genes.

REFERENCES

[1] de Necochea-Campio R, Chen C-S, Mirshahidi S, Howard FD, Wall NR. Clinico-pathologic relevance of Survivin splice variant expression. Cancer Lett. 2013;339:167–74.

[2] CE Desantis, J Ma MM Gaudet, LA Newman, KD Miller, Breast cancer statistics, 2019CA Cancer J Clin 2019; 69; 643-851.

[3] H Çiçek Ö Saygılı ÖN Sever V Kaya H Ulusal M Yıldırım The Diagnostic Role of A-kinase Anchoring Protein 12, Bcl-2 and High Mobility Group Box Protein-1 Levels in Breast CancerJ Oncol Sci201953905

[4] RL Siegel KD Miller A Jemal Cancer statisticsCA Cancer J Clin2018681730

[5] SJ Gould G Raposo As we wait: Coping with an imperfect nomenclature for extracellular vesiclesJ Extracell Vesicles2013210.3402/jev.v2i0.20389

[6] M Colombo G Raposo C Théry Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesiclesAnnu Rev Cell Dev Biol20143025589

[7] G Raposo HW Nijman W Stoorvogel R Liejendekker CV Harding CJ Melief B lymphocytes secrete antigen-presenting vesiclesJ Exp Med19961833116172

[8] G Raposo W Stoorvogel Extracellular vesicles: exosomes, microvesicles, and friendsJ Cell Biol2013200437383

[9] C Tetta E Ghigo L Silengo MC Deregibus G Camussi Extracellular vesicles as an emerging mechanism of cell-to-cell communicationEndocrine2013441119

[10] KW Witwer EI Buzas LT Bemis A Bora C Lässer J Lötvall Standardization of sample collection, isolation and analysis methods in extracellular vesicle researchJ Extracell Vesicles2013210.3402/jev.v2i0.20360

[11] M Colombo G Raposo C Thery Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesiclesAnnu Rev Cell Dev Biol20143025589

[12] OA Oto S Paydas K Tanriverdi G Seydaoglu S Yavuz U Disel Survivin and EPR-1 expression in acute leukemias: prognostic significance and review of the literatureLeuk Res200731111495501

[13] DC Altieri The case for survivin as a regulator of microtubule dynamics and cell-death decisionsCurr Opin Cell Biol20061860915

[14] S Khan JR Aspe MG Asumen F Almaguel O Odumosu S Acevedo-Martinez cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potentialBr J Cancer20091007107386

[15] T Dohi E Beltrami NR Wall J Plescia DC Altieri Mitochondrial survivin inhibits apoptosis and promotes tumorigenesisJ Clin Invest20041148111727

[16] PE Chugh SH Sin S Ozgur DH Henry P Menezes J Griffith Systemically Circulating Viral and Tumor-Derived MicroRNAs in KSHV-Associated MalignanciesPLoS Pathog201397e100348410.1371/journal.ppat.1003484

[17] T Umezu K Ohyashiki M Kuroda JH Ohyashiki Leukemia cell to endothelial cell communication via exosomal miRNAsOncogene2013222274755

[18] R Morton M Sayma MS Sura Economic analysis of the breast cancer screening program used by the UK NHS: should the program be maintained? Breast Cancer (Dove Med Press)2017921725

[19] X Yu SL Harris AJ Levine The regulation of exosome secretion: a novel function of the p53 proteinCancer Res200666947954801

[20] M Gunaldi N Isiksacan H Kocoglu Y Okuturlar O Gunaldi TO Topcu The value of serum survivin level in early diagnosis of cancerJ Cancer Res Ther20181435703

[21] S Wang J Xu Q Zhang Clinical significance of survivin and vascular endothelial growth factor mRNA detection in the peripheral whole blood of breast cancer patientsNeoplasma201663113340

[22] C Xu M Yamamoto-Ibusuki Y Yamamoto High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein levelBreast Cancer201421448290.

[23] Doucette T, Latha K, Yang Y, Fuller GN, Rao A, Rao G. Survivin transcript variant 2 drives angiogenesis and malignant progression in proneural gliomas. Neuro Oncol. 2014;16(9):1220–8.

[24] Khan S, Bennit HF, Wall NR. The emerging role of exosomes in Survivin secretion. Histol Histopathol. 2015;30(1):43–50.

[25] Valenzuela MMA, Ferguson Bennit HR, Gonda A, Diaz Osterman CJ, Hibma A, Khan S, Wall NR. Exosomes secreted from human cancer cell lines contain inhibitors of apoptosis (IAP). Cancer Microenviron. 2015;8(2):65–73.

[26] Miller R.L., Siegel K.D., Lin A., Mariotto A.B., Kramer J.L., Rowland J.H., et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 2016;66:271–289.

[27] Witjes J.A., Compérat E., Cowan N.C., De Santis M., Gakis G., Lebret T., et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol. 2014;65:778–792.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

[28] Felsenstein K.M., Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat. Rev. Urol. 2018;15:92–111.

[29] Lawrence M.S., Stojanov P., Polak P., Kryukov G.V., Cibulskis K., Sivachenko A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218.

[30] Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–322.

[31] Robertson A.G., Kim J., Al-Ahmadie H., Bellmunt J., Guo G., Cherniack A.D., et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–556.e25.

[32] Audenet F., Attalla K., Sfakianos J.P. The evolution of bladder cancer genomics: what have we learned and how can we use it? Urol. Oncol. 2018;36:313–320.

[33] Rodriguez-Vida A., Lerner S.P., Bellmunt J. The cancer genome atlas project in bladder cancer. Cancer Treat. Res. 2018;175:259–271.

[34] Warrick J.I., Walter V., Yamashita H., Chung E., Shuman L., Amponsa V.O., et al. FOXA1, GATA3 and PPAR cooperate to drive luminal subtype in bladder cancer: a molecular analysis of established human cell lines. Sci. Rep. 2016;6.

[35] Rosenberg J.E., Hoffman-Censits J., Powles T., van der Heijden M.S., Balar A.V., Necchi A., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920.

[36] Korpal M., Puyang X., Jeremy Wu Z., Seiler R., Furman C., Oo H.Z., et al. Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer. Nat. Commun. 2017;8:103.

[37] Goldstein J.T., Berger A.C., Shih J., Duke F.F., Furst L., Kwiatkowski D.J., et al. Genomic activation of PPARG reveals a candidate therapeutic axis in bladder cancer. Cancer Res. 2017;77:6987–6998.

[38] Halstead A.M., Kapadia C.D., Bolzenius J., Chu C.E., Schriefer A., Wartman L.D., et al. Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. Elife. 2017;6.

[39] Sweis R.F., Spranger S., Bao R., Paner G.P., Stadler W.M., Steinberg G., et al. Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol. Res. 2016;4:563–568.

[40] Davidson M.A., Mattison D.R., Azoulay L., Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit. Rev. Toxicol. 2018;48:52–108.

[41] Gampe R.T., Jr., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell. 2000;5:545–555.

[42] Rochel N., Krucker C., Coutos-Thévenot L., Osz J., Zhang R., Guyon E., et al. Recurrent activating mutations of PPARgamma associated with luminal bladder tumors. Nat. Commun. 2019;10:253.

[43] Marciano D.P., Kuruvilla D.S., Boregowda S.V., Asteian A., Hughes T.S., Garcia-Ordonez R., et al. Pharmacological repression of PPARgamma promotes osteogenesis. Nat. Commun. 2015;6:7443.

[44] Itoh T., Fairall L., Amin K., Inaba Y., Szanto A., Balint B.L., et al. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat. Struct. Mol. Biol. 2008;15:924–931.

[45] Brust R., Shang J., Fuhrmann J., Mosure S.A., Bass J., Cano A., et al. A structural mechanism for directing corepressor-selective inverse agonism of PPARgamma. Nat. Commun. 2018;9:4687.

[46] Shang J., Mosure S.A., Zheng J., Brust R., Bass J., Nichols A., et al. A molecular switch regulating transcriptional repression and activation of PPARgamma. Nat. Commun. 2020;11:956.

[47] Lamotte Y., Martres P., Faucher N., Laroze A., Grillot D., Ancellin N., et al. Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators. Bioorg. Med. Chem. Lett. 2010;20:1399–1404.

[48] Choi J.H., Banks A.S., Kamenecka T.M., Busby S.A., Chalmers M.J., Kumar N., et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5-mediated phosphorylation. Nature. 2011;477:477–481.

[49] Yasar P, Ayaz G, User SD, Gupur G, Muyan M. Molecular Mechanism of Estrogen-Estrogen Receptor Signaling. Reprod Med Biol (2017) 16:4–20. doi: 10.1002/rmb2.12006.

[50] Smith A, Rønnekleiv O, Kelly MJS. Gq-mER Signaling has Opposite Effects on Hypothalamic Orexigenic and Anorexigenic Neurons. Steroids (2014) 81:31–5. doi: 10.1016/j.steroids.2013.11.007.

[51] Prossnitz ER, Barton M. Estrogen Biology: New Insights Into GPER Function and Clinical Opportunities. Mol Cell Endocrinol (2014) 389:71–83. doi: 10.1016/j.mce.2014.02.002

[52] Jacenik D, Cygankiewicz AI, Krajewska WM. The G Protein-Coupled Estrogen Receptor as a Modulator of Neoplastic Transformation. Mol Cell Endocrinol (2016) 429:10–8. doi: 10.1016/j.mce.2016.04.011.

[53] Wong MM, Guo C, Zhang J. Nuclear Receptor Corepressor Complexes in Cancer: Mechanism, Function and Regulation. Am J Clin Exp Urol (2014) 2:169–87.

[54] Tang ZR, Zhang R, Lian ZX, Deng SL, Yu K. Estrogen-Receptor Expression and Function in Female Reproductive Disease. Cells (2019) 8:1123. doi:

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

ISSN: 2583-4053

Volume-1 Issue-5 || December 2022 || PP. 1-15

https://doi.org/10.55544/jrasb.1.5.1

10.3390/cells8101123.

[55] Xu Z, Zhang L, Yu Q, Zhang Y, Yan L, Chen Z-J. The Estrogen-Regulated lncRNA H19/miR-216a-5p Axis Alters Stromal Cell Invasion and Migration via ACTA2 in Endometriosis. Mol Hum Reprod (2019) 25:550–61. doi: 10.1093/molehr/gaz040.

[56] Artimani T, Saidijam M, Aflatoonian R, Amiri I, Ashrafi M, Shabab N, et al. Estrogen and Progesterone Receptor Subtype Expression in Granulosa Cells From Women With Polycystic Ovary Syndrome. Gynecol Endocrinol (2015) 31:379–83. doi: 10.3109/09513590.2014.1001733.

[57] Han SJ, Jung SY, Wu S-P, Hawkins SM, Park MJ, Kyo S, et al. . Estrogen Receptor β Modulates Apoptosis Complexes and the Inflammasome to Drive the Pathogenesis of Endometriosis. Cell (2015) 163:960–74. doi: 10.1016/j.cell.2015.10.034.

[58] Sanderson PA, Critchley HOD, Williams ARW, Arends MJ, Saunders PTK. New Concepts for an Old Problem: The Diagnosis of Endometrial Hyperplasia. Hum Reprod Update (2017) 23:232–54. doi: 10.1093/humupd/dmw042.

[59] Rodriguez AC, Blanchard Z, Maurer KA, Gertz J. Estrogen Signaling in Endometrial Cancer: A Key Oncogenic Pathway With Several Open Questions. Horm Cancer-Us (2019) 10:51–63. doi: 10.1007/s12672-019-0358-9.

[60] Hu GL, Zhang JB, Zhou XY, Liu JW, Wang Q, Zhang B. Roles of Estrogen Receptor Alpha and Beta in the Regulation of Proliferation in Endometrial Carcinoma. Pathol Res Pract (2020) 216:153149. doi: 10.1016/j.prp.2020.153149.

[61] Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. . Cell-Of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors From 33 Types of Cancer. Cell (2018) 173:291–304. doi: 10.1016/j.cell.2018.03.022.

[62] Backes FJ, Walker CJ, Goodfellow PJ, Hade EM, Agarwal G, Mutch D, et al. . Estrogen Receptor-Alpha as a Predictive Biomarker in Endometrioid Endometrial Cancer. Gynecol Oncol (2016) 141:312–7. doi: 10.1016/j.ygyno.2016.03.006

[63] Blanchard Z, Vahrenkamp JM, Berrett KC, Arnesen S, Gertz J. Estrogen-Independent Molecular Actions of Mutant Estrogen Receptor 1 in Endometrial Cancer. Genome Res (2019) 29:1429–41. doi: 10.1101/gr.244780.118.

[64] Rodriguez AC, Vahrenkamp JM, Berrett KC, Clark KA, Guillen KP, Scherer SD, et al. . ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells. Cancer Res (2020) 80:1234–45. doi: 10.1158/0008-5472.can-19-1382.

[65] Qi Y, Tan M, Zheng M, Jin S, Wang H, Liu J, et al. . Estrogen/estrogen Receptor Promotes the Proliferation of Endometrial Carcinoma Cells by Enhancing hMOF Expression. Jpn J Clin Oncol (2020) 50:241–53. doi: 10.1093/jjco/hyz174.

[66] D'Alonzo M, Bounous VE, Villa M, Biglia N. Current Evidence of the Oncological Benefit-Risk Profile of Hormone Replacement Therapy. Med (Kaunas Lithuania) (2019) 55:573. doi: 10.3390/medicina55090573.

[67] Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-Term Hormone Therapy for Perimenopausal and Postmenopausal Women. Cochrane Database Syst Rev (2017) 1:CD004143. doi: 10.1002/14651858.CD004143.pub5.

[68] Nijkang NP, Anderson L, Markham R, Manconi F. Endometrial Polyps: Pathogenesis, Sequelae and Treatment. SAGE Open Med (2019) 7:2050312119848247. doi: 10.1177/2050312119848247.

[69] Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, et al. . Clinico-Pathologic Comparison of Type II Endometrial Cancers Based on Tamoxifen Exposure. Gynecol Oncol (2017) 127:316–20.

[70] Carneiro ALB, Spadella APC, Souza FA, Alves KBF, Araujo-Neto JT, Haidar MA, et al. . Effects of Raloxifene Combined With Low-Dose Conjugated Estrogen on the Endometrium in Menopausal Women at High Risk for Breast Cancer. Clinics (Sao Paulo Brazil) (2021) 76:e2380.

[71] Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, et al. Protein-Coupled Estrogen Receptor-Selective Ligands Modulate Endometrial Tumor Growth. Obstet Gynecol Int (2019) 2019:472720.

[72] Komm BS, Mirkin S. An Overview of Current and Emerging SERMs. J Steroid Biochem Mol Biol (2021) 143:207–22.

[73] Altintas D, Kokcu A, Kandemir B, Tosun M, Cetinkaya MB. Comparison of the Effects of Raloxifene and Anastrozole on Experimental Endometriosis. Eur J Obstet Gyn R B (2018) 150:84–7.

[74] Haring J, Skrzypczak M, Stegerer A, Lattrich C, Weber F, Gorse R, et al. . Estrogen Receptor Beta Transcript Variants Associate With Oncogene Expression in Endometrial Cancer. Int J Mol Med (2012) 29:1127–36.

[75] Smuc T, Rizner TL. Aberrant Pre-Receptor Regulation of Estrogen and Progesterone Action in Endometrial Cancer. Mol Cell Endocrinol (2009) 301:74–82.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)